1. Market Research
  2. > Pharmaceutical Market Trends
  3. > South Korea Pharmaceuticals and Healthcare Report Q4 2016

South Korea Pharmaceuticals and Healthcare Report Q4 2016

  • October 2016
  • -
  • Business Monitor International
  • -
  • 111 pages

Includes 3 FREE quarterly updates
BMI View:

Significant regulatory changes in response to the illegal rebate scandal in South Korea will be unlikely. The country already has tough laws in place, which can be leveraged to impose tough penalties on Novartis and other firms practicing such sales tactics. Moreover, the pharmaceutical industry holds increasing importance to the country's economy, and the government has taken significant steps to foster its growth. This includes the pursuit of policies that depart from its focus on cost containment and instead accentuate the priority placed on the sector.

Headline Expenditure Projections

- Pharmaceuticals: KRW17,117bn (USD15.1bn) in 2015 to KRW17,666bn (USD14.9bn) in 2016; +3.2% in local currency terms and -1.0% in US dollar terms. Forecast broadly unchanged from previous quarter with US dollar amount revised upward.

- Healthcare: KRW116,599bn (USD103.1bn) in 2015 to KRW124,224bn (USD105.3bn) in 2016; +6.5% in local currency terms and 2.1% in US dollar terms. Forecast upgraded from previous quarter with an upgrade to US dollar value.

Table Of Contents

South Korea Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (South Korea 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (South Korea 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (South Korea 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (South Korea 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (South Korea 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (South Korea 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (South Korea 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (South Korea 2012-2020) 23
OTC Medicine Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (South Korea 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (South Korea 2014-2020) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (South Korea 2014-2020) 30
Industry Risk Reward Index 31
Asia Pacific Risk/Reward Index - Q4 2016 31
South Korea Risk/Reward Index 38
Rewards 38
Risks 38
Regulatory Review 40
Intellectual Property Issues 40
Pricing And Reimbursement Regime 41
Table: Different Price Control Levers 43
Market Overview 48
Healthcare Sector 48
Table: Healthcare Resources (South Korea 2010-2015) 49
Table: Healthcare Personnel (South Korea 2010-2015) 49
Table: Healthcare Activity (South Korea 2010-2015) 50
Research And Development 53
Clinical Trials 56
Epidemiology 57
Competitive Landscape 60
Research-Based Industry 60
Table: Multinational Market Activity 60
Generic Drugmakers 61
Pharmaceutical Distribution 63
Pharmaceutical Retail Sector 65
Table: Timeline Of Slow OTC Liberalisation 66
Company Profile 67
Daewoong Pharmaceutical 67
Dong-A Pharmaceutical 70
Eli Lilly 74
GlaxoSmithKline 77
Hanmi Pharmaceutical Co 80
Merck and Co 84
Novartis 87
Pfizer 91
Sanofi 94
Yuhan Corporation 97
Demographic Forecast 100
Demographic Outlook 100
Table: Population Headline Indicators (South Korea 1990-2025) 101
Table: Key Population Ratios (South Korea 1990-2025) 101
Table: Urban/Rural Population and Life Expectancy (South Korea 1990-2025) 102
Table: Population By Age Group (South Korea 1990-2025) 102
Table: Population By Age Group % (South Korea 1990-2025) 103
Glossary 105
Methodology 107
Pharmaceutical Expenditure Forecast Model 107
Healthcare Expenditure Forecast Model 107
Notes On Methodology 108
Risk/Reward Index Methodology 109
Index Overview 110
Table: Pharmaceutical Risk/Reward Index Indicators 110
Indicator Weightings 111

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.